Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R McKay

Showing results (831-840 of 932) with videos related to

Pageof 94
Sort By:
Molecular Oncology|February 19, 2021
Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinomaRory M Bade, Jennifer L Schehr, Hamid Emamekhoo, et al.
European Urology|February 11, 2026
FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and ApalutamidePaul L Nguyen, Marisa A Kollmeier, Dana E Rathkopf, et al.
The Prostate|November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancerChristopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
The Journal of Urology|March 8, 2021
Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate CancerRana R McKay, Wanling Xie, Huihui Ye, et al.
JCO Precision Oncology|February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumMaria I Carlo, Veda N Giri, Channing J Paller, et al.
The Oncologist|October 22, 2025
Genomic Alterations and Associated Outcomes in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer treated with 177Lu-PSMA-617Justine Panian, Nicholas C Henderson, Daniel Herchenhorn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2025
Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic SubtypesJustin Hwang, Pornlada Likasitwatanakul, Sachin Kumar Deshmukh, et al.
Cancer Research Communications|May 6, 2024
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human MalignanciesCarly D Miller, John R Lozada, Nicholas A Zorko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2024
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT TrialCharles B Nguyen, Melissa A Reimers, Chamila Perera, et al.
The Oncologist|June 27, 2023
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following ImmunotherapyJustine Panian, Ava Saidian, Kevin Hakimi, et al.
Pageof 94

Showing results (831-840 of 932) with videos related to

Sort By:
Pageof 94
Molecular Oncology|February 19, 2021
Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinomaRory M Bade, Jennifer L Schehr, Hamid Emamekhoo, et al.
European Urology|February 11, 2026
FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and ApalutamidePaul L Nguyen, Marisa A Kollmeier, Dana E Rathkopf, et al.
The Prostate|November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancerChristopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
The Journal of Urology|March 8, 2021
Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate CancerRana R McKay, Wanling Xie, Huihui Ye, et al.
JCO Precision Oncology|February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumMaria I Carlo, Veda N Giri, Channing J Paller, et al.
The Oncologist|October 22, 2025
Genomic Alterations and Associated Outcomes in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer treated with 177Lu-PSMA-617Justine Panian, Nicholas C Henderson, Daniel Herchenhorn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2025
Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic SubtypesJustin Hwang, Pornlada Likasitwatanakul, Sachin Kumar Deshmukh, et al.
Cancer Research Communications|May 6, 2024
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human MalignanciesCarly D Miller, John R Lozada, Nicholas A Zorko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2024
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT TrialCharles B Nguyen, Melissa A Reimers, Chamila Perera, et al.
The Oncologist|June 27, 2023
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following ImmunotherapyJustine Panian, Ava Saidian, Kevin Hakimi, et al.
Pageof 94